{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.8","upperLimit":"28.9","value":"20.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"}],"units":"Participants"}],"description":"Complete response rate is defined as the percentage of participants achieving a complete response (CR) based on the 2003 revised IWG criteria for AML as assessed by the investigator. CR for AML: - Absolute neutrophil count (ANC) \\> 1.0 x10⁹/L - Platelet count \\> 100 x10⁹/L - Bone marrow (BM) blasts \\< 5% - Absence of blasts with Auer rods - Independence of red cell transfusions","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG000","title":"Phase 2: Enasidenib 100 mg QD"}],"paramType":"NUMBER","populationDescription":"All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).","title":"Phase 2 Dose Expansion: Complete Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}